Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.
BMS announced the switch back to normal sales in a notice to 340B covered entities dated Oct. 1 on the U.S. Health Resources and Services Administration (HRSA) website. “At current time all limitations on purchasing of Vizada in the United States have been removed for 340B and non-340B entities,” the notice says. For roughly a year and a half, reduced sales to 340B covered entities and non-340B buyers have been based on customers’ historical purchasing patterns.
Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
